- Home
- VCEL vs TARS Comparison
VCEL vs TARS Comparison
Compare VCEL & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCEL
- TARS
- Stock Information
- Founded
- VCEL 1989
- TARS 2016
- Country
- VCEL United States
- TARS United States
- Employees
- VCEL N/A
- TARS N/A
- Industry
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- TARS Medicinal Chemicals and Botanical Products
- Sector
- VCEL Health Care
- TARS Health Care
- Exchange
- VCEL Nasdaq
- TARS Nasdaq
- Market Cap
- VCEL 2.1B
- TARS 1.7B
- IPO Year
- VCEL 1997
- TARS 2020
- Fundamental
- Price
- VCEL $35.61
- TARS $54.38
- Analyst Decision
- VCEL Strong Buy
- TARS Strong Buy
- Analyst Count
- VCEL 7
- TARS 7
- Target Price
- VCEL $61.29
- TARS $67.14
- AVG Volume (30 Days)
- VCEL 614.9K
- TARS 697.3K
- Earning Date
- VCEL 07-31-2025
- TARS 08-06-2025
- Dividend Yield
- VCEL N/A
- TARS N/A
- EPS Growth
- VCEL 2045.40
- TARS N/A
- EPS
- VCEL 0.13
- TARS N/A
- Revenue
- VCEL $249,119,000.00
- TARS $295,521,000.00
- Revenue This Year
- VCEL $23.03
- TARS $122.94
- Revenue Next Year
- VCEL $24.51
- TARS $44.14
- P/E Ratio
- VCEL $284.01
- TARS N/A
- Revenue Growth
- VCEL 16.13
- TARS 254.45
- 52 Week Low
- VCEL $33.09
- TARS $24.95
- 52 Week High
- VCEL $63.00
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- VCEL 42.13
- TARS 78.21
- Support Level
- VCEL $35.24
- TARS $40.55
- Resistance Level
- VCEL $38.08
- TARS $42.11
- Average True Range (ATR)
- VCEL 1.85
- TARS 2.09
- MACD
- VCEL -0.03
- TARS 1.37
- Stochastic Oscillator
- VCEL 27.62
- TARS 96.41
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.